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Ion-Channel Coupled Receptors: New Tools for the Study of Receptors
and Channels
Lydia N. Caro, Christophe J. Moreau, Argel Estrada-Mondrago´n,
Jean Revilloud, Michel Vivaudou.
Institut de Biologie Structurale, Grenoble, France.
Ligand-gated ion channels combine within a single polypeptide chain a binding
site for a specific signalling molecule and a selective ion-conducting pore, al-
losterically linked so that ligand binding controls pore opening, thus allowing
fast chemical-to-electrical signal transduction as required in synapses.
Ion Channel-Coupled Receptors (ICCRs) are artificial proteins comprised of
a G protein-coupled receptor fused to an ion channel, engineered to create
a physical coupling between ligand binding and channel gating. The ICCR con-
cept was previously validated with fusion proteins between the Kþ channel
Kir6.2 and either muscarinic M2, or dopaminergic D2 unmodified receptors
(Moreau et al., Nature Nanotech. 3:620-625, 2008). Here, we extend the con-
cept to the b2-adrenergic and the opsin receptors.
These receptors raised new challenges as they are significantly different from
M2 and D2 receptors in terms of structure (poor sequence homology, much lon-
ger cytoplasmic C-terminal), function (coupled to distinct G-proteins, distinct
effectors), and surface expression (extremely low in some cases in our Xenopus
oocyte heterologous expression system). We show here how surface expression
can be enhanced by co-expression of an accessory Kir6.2-binding protein, the
first transmembrane domain of the sulfonylurea receptor SUR, and how
receptor-channel coupling can be achieved by modifications of the receptors
that preserve their ligand-binding properties. The resulting b2 and opsin ICCRs
constitute blueprints for innovative tools to study the molecular mechanics of
receptors and channels and could find applications not only in diagnostics
and drug screening, but also in synthetic biology as adrenergic-gated and
light-gated Kþ channels.
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SUR1 L0 and Kir6.2 M0 can Partner in KATP Gating: Evidences from
Diabetogenic Mutations
Andrey Petrovich Babenko.
Pacific Northwest Research Institute and Diabetes Endocrinology Research
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Neonatal diabetes (ND) mutations in different domains of either KATP subunit
overactivate KATP via different mechanisms. Mutations in the ABC core of
SUR1 augment its Mg-nucleotide-dependent stimulation of Kir6.2. Mutations
at the putative ATP site of Kir6.2 supposedly compromise the inhibitory nucle-
otide binding. Mutations at the putative gate reportedly stabilize its open state.
Many ND mutations map to the putative L0 helix preceding the SUR1 core
and to theM0 (‘slide’) helix of Kir6.2.We discovered that L0 controls spontane-
ous bursting and introduced amodel inwhich L0 andM0 partner inKATPgating
(Babenko & Bryan 2003). The model predicted that ND mutations in either am-
phipathic helix at the membrane-cytosol interface hyperactivate KATP by alter-
ing its intrinsic gating kinetics. Here we tested the idea.We compared the effects
of severe ND mutations in the middle of either interface helix on spontaneous
single-channel kinetics, ATP-inhibition, and Mg-nucleotide stimulation of
KATP. We found that each of these mutations decreases the rate of burst termi-
nationwhile increasing the rate of burst initiation, thereby reducing the availabil-
ity of the closed state with the lowest Kd for inhibitory ligands. This mechanism
attenuates ATP inhibition but not Mg-nucleotide stimulation, thereby hyperacti-
vating KATP in vivo, and uncouples sulfonylurea binding from Kir6.2 closure.
Thus, in support of our model, perturbing either interface helix disrupts SUR1/
Kir6.2 inhibitory coupling. Affinity photolabelingwith I-azidoglibenclamide in-
dicated that noneof theNDmutations altered the proximity ofL0 toM0.But each
of thesemutations changed the helical hydrophobic moment, implying that rota-
tion of either helix along its axis disruptsL0/M0 interactions.Wepropose that the
two interface helices have been optimized to interact and slide together to stabi-
lize the long-lived closed state of SUR1/Kir6.2 complex.
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ATP-sensitive Kþ (KATP) channels, comprised of pore-forming Kir6.x and reg-
ulatory SURx subunits, play important roles in many cellular functions. Vascu-
lar (Kir6.1/SUR2B) and non-vascular (Kir6.2/SUR2B) smooth muscle KATP
channels regulate the resting membrane potential in smooth muscle cells andmodulate the muscle tone. In spite of the fact that Kir6.1 and Kir6.2 share
~70% sequence identity, their sensitivity to ATP inhibition differs by more
than 30-fold with IC50 values of 3.151.3mM (n=7) and 101522mM (n=17),
respectively. We investigated the molecular mechanisms that underlie this dif-
ferential response. All (17) Kir6.2 residues putatively involved in binding of
ATP are conserved in Kir6.1 with the exception of K39 and K185. We con-
structed a homology model of Kir6.2 and carried out computational docking
of ATP to determine the conformation of bound ATP in its putative binding
site. The model was validated by assessing the binding free-energy difference
of ATP for wild-type (Kir6.2/SUR2B) and a range of Kir6.2 ATP-binding site
mutants for which the affinity for ATP was previously experimentally deter-
mined. The model predicted that substitution of K39 and K185 on Kir6.2
with the equivalent residues on Kir6.1 (K39S/K185R) did not affect the ATP
affinity. Patch-clamp experiments confirmed that there was no difference in
the ATP sensitivity between these channels. Furthermore, the open probability
(Po) of Kir6.1/SUR2B, Kir6.2/SUR2B and Kir6.2-K39S-K185R/SUR2B were
identical (0.4150.05 (n=7), 0.3850.06 (n=7) and 0.4550.02 (n=8), respec-
tively), indicating that their different ATP sensitivity is not caused by a change
in channel gating. In conclusion, the difference in ATP sensitivity between
Kir6.1 and Kir6.2 is not caused by a difference in the ATP binding site meaning
other regions of the channel must be involved.
This work was supported by BBSRC (BB/H000259/1) and by CASPUR
(gpu11-905)
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Patient-Specific Inducible Pluripotent Stem Cells Reveal Mechanism of
Personalized Therapy for an Inherited Cardiac Arrhythmia
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We report a study using inducible pluripotent stem cells (iPSCs) designed to
unravel the mechanistic basis for resistance to previously prescribed gene-
specific therapy for a patient carrying a Long QT Syndrome variant 3
(LQT3) mutation. The previous therapy, treatment with the Naþ channel
blocker mexiletine, had been based on previous heterologous expression stud-
ies. In contrast to previous predictions arrhythmias in the proband have not
been controlled by mexiletine, which has had a limited therapeutic dose range
because of increased clinical risk found at high doses. The proband harbors a de
novoSCN5A mutation (F1473C) and is heterozyous in KCNH2 (K897/T897).
Both parents lack the SCNA5 mutation and each is homozygous for either
T897 or K897 KCNH2. Cardiomyocytes (hiPSC-CMs) were derived from
hiPSCs produced by lentiviral reprograming of skin fibroblasts. Whole-cell
patch clamp was performed on single hiPSC-CMs from each family member
and confirmed dysfuntional Naþ channel inactivation in cells from the proband
but neither parent which was corrected by mexiletine (50 mM). However this
same mexiletine concentration was found to also have sginficant off-target
block of L-type calcium and IKr potassium channels, which may explain the pa-
tient’s suboptimal response to the therapeutic regimen and limited useful ther-
apeutic dose range of the drug. Instead of raising drug concentration we show
that increased heart rate, which in the patient is controlled by an implantable
cardioverter-defibrillator (ICD), effetively and markedly inhibits dysfunctional
Naþ channel activity in these cells and has markedly suppressed arrhythmic
events in the proband. These results demonstrate the power and utility of iPSCs
in detecting mechanisms of disease and optimizing its treatment in patient-
specific manner.
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Alternating Cycle Lengths Increases Dispersion of Action Potential Dura-
tions (APD) in Transgenic Rabbit Model of Long QT Syndrome Type 2
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Long QT syndrome Type 2 (LQT2) is a congenital disease with abnormal
prolongation of APD and sudden cardiac death (SCD) due to polymorphic ven-
tricular tachycardia (pVT). These arrhythmias are often preceded by a charac-
teristic initiation mode of short-long-short alternating cycle lengths (CL) in
surface electrocardiograms. We hypothesized that alternating CLs in LQT2
cause increased APD dispersion, which may promote reentry formation.
